iifl-logo

Mankind Pharma Ltd Dividend

2,590.9
(0.81%)
Sep 18, 2025|12:49:58 PM

Mankind Pharma CORPORATE ACTIONS

18/09/2024calendar-icon
18/09/2025calendar-icon
PurposeAnnouncement DateEx-DateRecord DateDividend AmountDividend per ShareRemark
Dividend31 Jul 20258 Aug 20258 Aug 20251100Interim
approved the payment of interim dividend of ? 1/- per equity share i.e. 100% on face value of ? 1/- per equity share for the Financial Year 2025-26 and in terms of Regulation 42 of the Listing Regulations, Board has fixed Friday, August 8, 2025, as the Record Date for the purpose of ascertaining the eligibility of shareholders for payment of interim dividend. Same would be paid within 30 days from the date of declaration.

Mankind Pharma: Related News

Mankind Pharma Q1 Updates: Net profit down ~18%

The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.

1 Aug 2025|01:41 PM
Read More
Top Stocks for Today - 01st August 2025

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

1 Aug 2025|08:58 AM
Read More
Mankind Pharma posts mixed performance in Q4; stock slips ~4%

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.

22 May 2025|12:15 PM
Read More
Top Stocks for Today - 22nd May 2025

Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.

22 May 2025|06:38 AM
Read More
Mankind Pharma Faces ₹183.11 Crore Tax Demand

The cumulative demand, including interest charges, is ₹183.11 crore.

30 Mar 2025|04:34 PM
Read More
Mankind Pharma Merges Three Subsidiaries

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

30 Mar 2025|01:33 PM
Read More
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

28 Feb 2025|11:13 PM
Read More
Top Stocks for Today - 24th January 2025

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

24 Jan 2025|07:50 AM
Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

23 Jan 2025|11:57 PM
Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

8 Jan 2025|04:01 PM
Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.